News

Vertex's trial failure, scrapped study cloud pain drug push; shares slump
Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...
Cedar Park's Firefly Aerospace soars to $9.8B valuation in trading debut
Firefly Aerospace soared in its public market debut Thursday, beginning trading at $70, over 55% higher than its IPO price.
Texas’ Firefly Aerospace ignites rocket engine for its Nasdaq debut
Shares for Central Texas-based Firefly Aerospace began trading on the Nasdaq market Thursday. The company, which landed a ...
Vertex targets $750M–$754M 2025 revenue while advancing e-invoicing expansion
Discover key insights from Vertex, Inc.'s Q2 2025 earnings: solid revenue growth, macro challenges, and a focus on e-invoicing opportunities.
Vertex reiterates $11.85B–$12B 2025 revenue guidance while boosting JOURNAVX commercial investment
Discover how Vertex Pharmaceuticals achieved 12% Q2 2025 revenue growth with new launches like ALYFTREK, CASGEVY, & JOURNAVX.
MarketBeat on MSN2d
Vertical Aerospace's New Deal and Earnings De-Risk Production
In the first week of August 2025, Vertical Aerospace (NYSE: EVTL) announced a long-term strategic partnership with Aciturri Aerostructures, a major global supplier with deep roots in the traditional ...